Controversies in new antibiotic therapy for ambulatory patients
- First Online:
- Cite this article as:
- Sundararajan, V., Rubenstein, E., Rolston, K. et al. Support Care Cancer (1997) 5: 358. doi:10.1007/s005200050092
- 23 Views
The care of the febrile neutropenic patient has undergone a shift in the last 10 years with the realization that neutropenic patients presenting with fever do not constitute a homogeneous group. Strategies of risk assessment have allowed the testing of novel therapies including oupatient treatment with oral and intravenous antibiotics, either in combination regimens or as monotherapy; the addition of growth factors to hasten the return of the absolute neutrophil count; and the possibility of self-initiation of antibiotics by cancer patients when they develop fever. The clinical trials data regarding these new approaches will be reviewed, and areas requiring further research will be discussed.